NCT05879978: A trial that was reported late by Boehringer Ingelheim
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT05879978 |
|---|---|
| Title | A Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Obrixtamig (BI 764532) Combined With Ezabenlimab in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 27, 2023 |
| Completion date | Dec. 26, 2025 |
| Required reporting date | Dec. 26, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 27, 2025 |
| Days late | None |